8 news items
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
VIR
24 May 24
Buy
$110.00
-
Key Insights:
Action Taken: In response to dynamic
Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
VIR
22 May 24
into virologic response rates, ALT normalization, and durability of viral suppression."
Presentation details
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
VIR
21 May 24
acid (siRNA) that Vir believes has the potential to stimulate an effective immune response and have direct antiviral activity against hepatitis B
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
VIR
13 May 24
the potential to stimulate an effective immune response and has direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
VIR
7 May 24
, it signifies their response to recent developments related to Vir Biotechnology. This offers insight into analysts' perspectives on the current state
ciphgojas5bvccfdfxel9dx 58pdh5jthpwnaekg6fl8lzo9ezp
ANTX
VBIV
VIR
22 Mar 24
trigger a potent and specific immune response in chronic Hepatitis B (CHB) patients and linking that response to improved clinical outcomes
5js3uuq113x yaql4fplqaelo0
VIR
15 Mar 24
Key Insights:
Action Taken: In response to dynamic market conditions and company performance
anxj7um2vrbot stg2qv6ncj2wnh1jgc
VIR
5 Mar 24
virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an immune response and have direct antiviral
- Prev
- 1
- Next